Contera Pharma announces first patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease

Posted on by stom_admin

Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the dosing of the first patient in a Phase 1b pharmacoscintigraphic study evaluating CP-012. This novel delayed-release, dual-pulse levodopa/carbidopa tablet is designed to address the distinct challenges of nocturnal immobility and early morning akinesia in Parkinson’s disease (PD) patients. These […]

Contera Pharma announces management changes to secure progression of lead programs and further expansion of pipeline

Posted on by stom_admin

[Hørsholm, September 6, 2024] – Contera Pharma A/S, a clinical-stage biotech company developing innovative therapies to treat neurological disorders, is pleased to announce key changes to its leadership team. These strategic appointments underscore the company’s commitment to advancing clinical excellence, financial integrity, and scientific innovation. Contera Pharma has welcomed Dr. Anne Birk Østerskov as Chief […]

Contera Pharma reports topline results from its Phase IIb clinical trial ASTORIA, evaluating JM-010 for treatment of Parkinson’s disease dyskinesia

Posted on by stom_admin

[Hørsholm, May 21st, 2024] – Contera Pharma A/S, a biotech company developing innovative therapies to treat neurological disorders, announce topline results from the ASTORIA Phase IIb trial of JM-010 in people suffering from dyskinesia in Parkinson´s disease.  The main objectives of the trial were to investigate efficacy and safety of two doses of JM-010, compared […]

Last patient enrolled in the ASTORIA Phase 2b clinical trial evaluating JM-010, an innovative therapy to treat Parkinson’s disease dyskinesia

Posted on by stom_admin

[Hørsholm, January 17th, 2024] – Contera Pharma A/S, a biotech company developing innovative therapies to treat neurological disorders, announce enrolment of the last patient in its Phase 2b clinical trial ASTORIA. The trial aims to evaluate the efficacy of JM-010, a novel therapeutic solution designed to specifically address the pathophysiology underlying Parkinson’s disease dyskinesia. This […]